市場調查報告書

全球肝素市場:成長,趨勢,及預測

Heparin Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921956
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
全球肝素市場:成長,趨勢,及預測 Heparin Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 115 Pages
簡介

本報告提供全球肝素市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,產品·原料·給藥途徑·用途·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 慢性疾病盛行率的增加
    • 老年人口的增加
  • 市場阻礙因素
    • 肝素的副作用
  • 波特的五力分析

第5章 市場區隔

  • 各產品
    • 未分級肝素
    • 低分子量肝素(LMWH)
    • 超低分子量肝素(ULMWH)
  • 各原料
    • 豬隻
  • 各給藥途徑
    • 口服
    • 非口服
  • 各用途
    • 心房纖維顫動·心臟病發作
    • 中風
    • 深部靜脈血栓症(DVT)
    • 肺動脈栓塞(PE)
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Aspen Holding
    • B Braun Melsungen AG
    • Baxter
    • Bioiberica
    • Dr. Reddy's Laboratories
    • Hebei Changshan Biochemical Pharmaceutical
    • Leo Pharma
    • Opocrin
    • Pfizer
    • Shenzhen Hepalink Pharmaceutical Group

第7章 市場機會及今後趨勢

目錄
Product Code: 67676

Market Overview

Heparin is a medication and naturally occurring glycosaminoglycan, which is used as an anticoagulant (blood thinner). Specifically, it is also used in the treatment of heart attacks and unstable angina. It is usually given by injection into a vein or under the skin or in oral for in some cases.

Recently, due to an increase in mortality and prevalence of chronic diseases like cardiovascular disorders. As heparin acts as an anticoagulant that prevents the formation of blood clots, it is used before surgery to reduce the risk of in the veins, arteries, or lungs. As a result, the demand for heparin has increased. Moreover, the geriatric population is more prone to such chronic diseases, and hence, increasing the geriatric population is also increasing the demand for these surgeries. These factors have helped the growth if the market.

However, side-effects of heparin are refraining the patients from its use. This is restraining market growth.

Scope of the Report

Heparin is used as an anticoagulation agent which allows the body's natural clot lysis mechanisms to work normally to break down clots that have formed.

In the report, a detailed analysis of the heparin market is provided. The market is evaluated by collating revenues generated across segments, categorized by Product, Source Mode of Administration, Application, and Geography.

Key Market Trends

Parenteral administered medication is expected to dominate the market

While heparin does not break down clots that have already formed (unlike tissue plasminogen activator), it allows the body's natural clot lysis mechanisms to work normally to break down clots that have formed. Heparin is generally used for anticoagulation for the following conditions including Acute coronary syndrome, Atrial fibrillation, etc. These disorders are linked to several forms of cardiovascular disease like high blood pressure, coronary artery disease, hypertrophic cardiomyopathy (HCM), pericarditis, congenital heart disease, and previous heart surgery.

Moreover, cardiovascular disease is the leading global cause of death, accounting for more than 17.6

million deaths per year in 2016, a number that is expected to grow to more than 23.6 million by

2030, according to a 2014 study.

North America is Expected to Dominate the Market

According to the American Heart Association, cardiovascular disease (CVD), listed as the underlying cause of death, accounting for 840,678 deaths in the United States (US) in 2016, which is approximately 1 of every 3 deaths. In Mexico, CVD mortality is 292 per 100 000 population according to a 2015 OECD report. However, this rate is expected to increase in the future due to high obesity and diabetes rates. According to the Public Health Agency of Canada 2017 report, about 2.4 million, accounting for 8.5% of Canadian adults aged 20 years and older live with diagnosed ischemic heart disease, including 578,000 (2.1%) with a history of a heart attack. The high rate of CVD directly impacts the rate of surgeries for CVDs, which in turn positively impacts the heparin market.

Moreover, the United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development. These policies encourage global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players. As high and increasing demand is met by the presence of global players in the region, the heparin market is further expected to increase.

Competitive Landscape

The majority of the heparin is being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market grow.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Chronic Diseases
    • 4.2.2 Rise in Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of Heparin
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Unfractionated Heparin
    • 5.1.2 Low Molecular Weight Heparin (LMWH)
    • 5.1.3 Ultra-Low Molecular Weight Heparin (ULMWH)
  • 5.2 By Source
    • 5.2.1 Bovine
    • 5.2.2 Porcine
  • 5.3 By Mode of Administration
    • 5.3.1 Oral
    • 5.3.2 Parenteral
  • 5.4 By Application
    • 5.4.1 Atrial Fibrillation & Heart Attack
    • 5.4.2 Stroke
    • 5.4.3 Deep Vein Thrombosis (DVT)
    • 5.4.4 Pulmonary Embolism (PE)
    • 5.4.5 Others
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Aspen Holding
    • 6.1.2 B Braun Melsungen AG
    • 6.1.3 Baxter
    • 6.1.4 Bioiberica
    • 6.1.5 Dr. Reddy's Laboratories
    • 6.1.6 Hebei Changshan Biochemical Pharmaceutical
    • 6.1.7 Leo Pharma
    • 6.1.8 Opocrin
    • 6.1.9 Pfizer
    • 6.1.10 Shenzhen Hepalink Pharmaceutical Group

7 MARKET OPPORTUNITIES AND FUTURE TRENDS